Linda A.Hesse

Partner

巴黎 + 33.1.56.59.38.72

Linda Hesse advises clients in the areas of capital markets, securities law, public M&A, and corporate governance under both U.S. and French law. She acts for issuers with respect to their issuances of debt and equity securities; listings on Euronext, Nasdaq, and the NYSE; and on regulatory matters involving the SEC and the French Financial Markets Authority (AMF). Linda also advises financial institutions as advisors in offerings of equity, debt, and complex instruments. Her practice includes advising on environmental, social, and governance (ESG) matters, including sustainable finance transactions, green frameworks, ESG disclosures, and risk assessments.

Notable issuer clients include Orange for ongoing securities compliance, debt and equity offerings, and M&A; Sanofi on its ongoing SEC compliance and U.S. shelf program, including its $7 billion Yankee bond offering in connection with its Genzyme acquisition; and EDAP TMS on ongoing securities compliance and equity offerings.

Investment bank clients include BNP Paribas, Crédit Agricole CIB, Natixis, and SVB Leerink. Notable underwriter engagements include representing the underwriters on Genfit's Nasdaq IPO (with respect to French law), Medincell's IPO on Euronext Paris, and Sequans' NYSE IPO.

Linda also advises companies on cross-border public M&A transactions, including Panalpina on its acquisition by DSV; Stallergenes Greer in connection with the take private transaction by Waypoint; Kildare Partners on its acquisition of Technopolis Plc; Safran on its acquisition of Zodiac Aerospace; Total on its investment in Clean Energy Fuels; and Orange on the Jazztel acquisition.

Linda is a member of the International Bar Association and active in the Securities Law Committee.

经验

  • Voltalia issues inaugural green bondsJones Day represented Voltalia in connection with its inaugural green bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs Vertes) due 2025 for a nominal amount of approximately €200 million as well as within the implementation of its Green & Sustainability-linked Financing Framework.
  • Syndicate of leading banks complete €715 million share capital increase by Tikehau CapitalJones Day advised Berenberg, Credit Suisse, Natixis, BNP Paribas, Crédit Agricole Corporate and Investment Bank, and Société Générale, as global coordinators, joint lead managers and joint bookrunners, and Citigroup and RBC Capital Markets, as joint lead managers and joint bookrunners, in connection with the €715 million share capital increase without shareholders' preferential subscription rights and with a priority subscription period for existing shareholders by Tikehau Capital, an asset management and investment group.
  • Bryan, Garnier & Co Limited and Chardan Capital Markets complete €25 million private placement of shares by GenSight Biologics S.A.Jones Day represented Bryan, Garnier & Co Limited and Chardan Capital Markets, LLC in connection with the €25 million private placement of shares by GenSight Biologics S.A., a French clinical-stage gene therapy company in the area of severe retinal neurodegenerative diseases.
  • Selectirente completes €217 million capital increaseJones Day represented Selectirente S.A. in connection with the €217 million share capital increase without preferential subscription rights but priority subscription period granted to the existing shareholders.
  • Panalpina and DSV join forces by way of CHF 4.6 billion (US$4.6 billion) public exchange of stockJones Day advised Panalpina Welttransport (Holding) AG, Basel, Switzerland, one of the world's leading freight forwarders, with respect to German, EU, and U.S. securities law aspects and foreign direct investment filings in connection with the combination with DSV A/S, Hedhusene, Denmark, by way of a CHF 4.6 billion (US$4.6 billion) public exchange offer of DSV to all Panalpina shareholders to tender their Panalpina shares (listed at SIX Swiss Exchange) against DSV shares (listed at NASDAQ Copenhagen).
  • Orocobre raises A$156 million by way of placement and share purchase planJones Day advised Orocobre Limited, a dual ASX and TSX-listed lithium chemicals producer, on a A$156 million capital raising by way of a fully underwritten placement to institutional investors of A$126 million and non-underwritten share purchase plan to shareholders in Australia and New Zealand of up to A$30 million.
  • Natixis, ODDO BHF SCA, and Bryan, Garnier & Co Limited complete €37 million private placement of shares by CarbiosJones Day represented Natixis, ODDO BHF SCA, and Bryan, Garnier & Co Limited, as joint global coordinators, joint lead managers, and joint bookrunners, in connection with the €37 million private placement of shares of Carbios, a French green chemistry company.
  • SVB Leerink, Barclays, Bryan Garnier, and Natixis underwrite $155.4 million Nasdaq IPO by GenfitJones Day acted as French counsel to the underwriters, led by SVB Leerink and Barclays, as global coordinators, and Bryan Garnier and Natixis, as European bookrunners, in connection with the initial public offering of Genfit S.A., a French Euronext Paris-listed biotechnology company on Nasdaq for a total aggregate amount of $155.4 million, after full exercise of the over-allotment option.
  • Largest Cineworld shareholder refinancesJones Day advised Global City Theatres B.V., (GCT), the largest shareholder of Cineworld Group plc (Cineworld), Regal in the U.S., as lead counsel on its debt refinancing and related capital market aspects.
  • Belfius Bank and Kempen complete €69 million placement of treasury shares by BefimmoJones Day assisted joint bookrunners Belfius Bank SA and Kempen & Co. in connection with the €69 million (US$75.5 million) placement of treasury shares by Befimmo SA, a REIT listed on Euronext Brussels, to qualified investors in Belgium, the European Economic Area, and to a limited number of qualified institutional buyers within the U.S.
  • CARMAT completes €60 million reserved offering for specialized and strategic investorsJones Day advised CARMAT SA, a designer and developer of the world's most advanced heart project, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, in connection with its €60 million (US$66.3 million) share capital increase, reserved for investors, specialists of the healthcare and life sciences industry, or strategic partners of CARMAT.
  • Joh. Berenberg, Gossler & Co. KG; Gilbert Dupont; and Louis Capital Markets complete IPO of Ordinary Shares of Nacon S.A. on regulated market of Euronext in ParisJones Day advised Joh. Berenberg, Gossler & Co. KG; Gilbert Dupont; and Louis Capital Markets UK LLP in connection with the €100 million initial public offering of Ordinary Shares of Nacon S.A., a French company specialized in the development of video games and gaming accessories, on the regulated market of Euronext in Paris.
  • Alchimie completes €17.9 million IPO of Ordinary SharesJones Day advised Alchimie SAS, a French OTT subscription video on demand platform, in connection with the €17.9 million initial public offering of Ordinary Shares listed on the multilateral trading facility of Euronext Growth Paris.
  • Gilbert Dupont; Joh. Berenberg, Gossler & Co. KG; and Portzamparc complete IPO of BoostheatJones Day advised Gilbert Dupont; Joh. Berenberg, Gossler & Co. KG; and Portzamparc, as joint global coordinators, joint lead managers, and joint bookrunners, in connection with the initial public offering of Boostheat SA, a designer, developer, and producer of technologically advanced, energy efficient, and sustainable heating solutions, on the regulated market of Euronext in Paris.
  • Stallergenes Greer plc acquired by Waypoint for approximately €110 million (US$124 million)Jones Day advised Stallergenes Greer plc in the recommended cash acquisition by Ares Life Sciences I S.à r.l. (Waypoint) of the entire issued, and to be issued, ordinary share capital of Stallergenes Greer not held directly or indirectly by Waypoint by way of a scheme of arrangement for approximately €110 million (US$124 million).
  • Athyrium Capital Management partially issues second tranche of bond issueJones Day advised Athyrium Capital Management, LP in connection with the partial issuance of the second tranche of its bond issue.
  • 演讲

    • June 2, 2020
      COVID-19-Related Transparency and Insider Trading Discussion – A Global Perspective
    • September 12, 2019
      Sustainable Economy: A Global View
    • 15 novembre 2017
      Biotech/Medtech, comment se financer aux États-Unis?
    • November 15, 2017
      Biotech/Medtech, how to raise funds in United States?
    • October 23, 2017
      Seminar for Listed Companies: What You Need to Know About Recent Legal Developments
    • 17 octobre 2017
      Enquêtes internes vs. Enquêtes judiciaires : les liaisons dangereuses ?
    • September 13, 2017
      ECM Round Table: Market Trends and Landmark Deals 2017, Organized by the Magazine des Affaires, Paris
    • 13 septembre 2017
      Table ronde Equity Capital Markets (ECM) : Tendances et opérations emblématiques 2017 – Organisée par le Magazine des Affaires, Paris
    • 20 avril 2017
      Finale de la 3ème édition du Prix Jones Day/ESSEC/Paris II
    • November 9, 2016
      Jones Day Global Life Sciences Conference – 2016 Issues & Trends
    • 7 janvier 2015
      U.S. IPOs : How and Why
    • 13 novembre 2014
      The ABA's 15th Annual "Live from the SEC"
    • October 6, 2014
      BioM-Forum: IPO in the US - a reality
    • 22 septembre 2014
      4ème Dîner-Débat "HEC au Féminin"
    • February 14, 2013
      European Banking – On the Road to Union and Harmonization?
    • Jeudi 17 janvier 2013
      Introduction en bourse aux Etats-Unis et le JOBS Act : enjeux et problématiques
    • September 20, 2012
      SME Financing: legal news and market trends – in collaboration with NYSE Euronext and Société Générale
    • 20 septembre 2012
      Le financement des PME: actualités juridiques et tendances de marché - en partenariat avec NYSE Euronext et Société Générale
    • June 30, 2011
      Managing Your Risk - Bribery, Corruption and Business Ethics
    • 23 mai 2011
      Les femmes et le private equity : les nouvelles frontières de la région Moyen-Orient/Afrique du Nord, Séminaire organisé par Venture Catalyst Private Equity Partners avec le soutien de MENA-OCDE Women’s Business Forum, du MENA-OCDE Investment Programme, du Département d’Etat et du Département du Commerce des Etats-Unis
    • May 23, 2011
      Women in Private Equity: New Frontiers for the MENA Region
    • 2 mai 2011
      S’informer et échanger pour mieux administrer - Dîner-débat organisé par HEC au Féminin
    • May 2011
      Managing your Risk - Bribery, Corruption and Business Ethics
    • 27 janvier 2011
      Opérations de Spin-off - enjeux et modalités juridiques : La mise en oeuvre des opérations de spin-off, 2ème volet
    • 9 décembre 2010
      Opérations de Spin-off - enjeux et modalités juridiques : Enjeux réglementaires et opportunités, 1er volet
    • 4 juillet 2007
      Les prises de contrôle rampantes, Association des Juristes de Sciences Po
    • July 4, 2007
      Les prises de contrôle rampantes, Association des Juristes de Sciences Po
    • 3 avril 2007
      Introductions en bourse : feuille de route pratique
    *We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.